甘露聚糖肽序贯联合化疗治疗晚期食道癌的临床观察  

Clinical Observation of Mannatide Sequential Therapy Combined with Chemotherapy in Advanced Esophageal Cancer

作　　者：索凤茹[1] 金迎[1] 

机构地区：[1]辽宁中医药大学附属第二医院肿瘤科,沈阳110000

出　　处：《中国医药导刊》2014年第8期1224-1225,1223,共3页Chinese Journal of Medicinal Guide

摘　　要：目的：探讨甘露聚糖肽序贯疗法联合化疗治疗晚期食道癌的临床疗效及安全性。方法：2010年3月～2013年4月选择69例晚期食道癌患者，随机平均分为三组，治疗组、对照组、空白组，三组均采用PF方案化疗，同时治疗组患者住院期间静脉滴注甘露聚糖肽注射液，出院后口服甘露聚糖肽口服液；对照组患者住院期间静脉滴注胸腺肽注射液，出院后口服胸腺肽肠溶片；空白组患者住院期间静脉点滴同体积的氯化钠注射液，出院后口服等量的安慰剂。结果：治疗组临床总有效率为86.96%，与空白组临床总有效率比较差异具有统计学意义（P=0.044），但与对照组比较差异无统计学意义（P=0.43）。治疗组消化道反应、白细胞下降、血小板下降发生率分别为39.13%、17.39%、0，与对照组消化道反应发生率、白细胞下降发生率等比较差异具有统计学意义（P值分别为0.017、0.028）。治疗组患者1年生存率、3年生存率与对照组、空白组比较差异均具有统计学意义（P〈0.05）。结论：甘露聚糖肽序贯疗法能显著提高晚期食道癌患者化疗的临床疗效，降低化疗所致毒副反应发生率，延长患者生存期，其效果优于胸腺肽。To observe the clinical efficacy and safty of Mannatide sequential therapy combined with chemotherapy in advanced esophageal cancer.Methods： 69 cases of advanced esophageal cancer patients from March 2010 to April 2013 were randomly divided into three groups： the treatment group, the control group and the blank group. Three groups were given PF chemotherapy. Patients in the treatment group were given intravenous Mannatide injection during hospitalization and oral Mannatide after discharge. Patients in the control group were given intravenous Thymosin injection during hospitalization and oral Thymosin enteric-coated after discharge. Patients in the blank group were given the same volume of intravenous sodium chloride injection and the same amount of a placebo orally after discharge.Results：The total effective rate in treatment group 86.96%, with statistically significant difference between that of the control group （P=0.044）, but the difference compared with the control group was not statistically significant （P=0.43）. The rates of gastrointestinal reactions, leukopenia, thrombocytopenia in treatment group were 39.13%, 17.39%, 0, with statistically significant differences between that of the control group （P=0.017, respectively, 0.028）. The 1-year and 3-year survival rates in treatment patients were with statistically significant differences between that of the control group and blank group （P〈0.05）.Conclusion：The Mannatide sequential therapy could significantly improve the clinical efficacy of chemotherapy in patients with advanced esophageal cancer, reduce the incidence of chemotherapy-induced toxicity and prolong survival time. The efficacy was better than Thymosin.

关 键 词：甘露聚糖肽 序贯 食道癌 化疗 

分 类 号：R735.1[医药卫生—肿瘤]